Stanley Lambertus Stargardt disease – Toward clinical trials
Arguably the most prevalent inherited retinal disorder is Stargardt disease.read more
Stanley Lambertus Stargardt disease – Toward clinical trialsOver 7000 rare diseases exist, and together, they afflict millions of patients worldwide. For these patients, there is promising and encouraging progress in finding a cure. However, no treatment is available for the majority of these diseases. Arguably the most prevalent inherited retinal disorder is Stargardt disease. In its natural course, the heterogeneity in the age at onset reflects the vast heterogeneity in variable rates of functional and structural disease progression. Herein, not only do the challenges of treatment evaluation—which have been present since ancient history—apply, but its rare nature and heterogeneity also pose additional challenges. This thesis responds to those challenges in treatment evaluation for Stargardt disease, providing a strategy for future studies which aim to identify an effect of novel treatments for rare diseases.
Date, time and location PhD defense
- Date: 21 December 2018
- Time: 12.30 hrs
- Location: Radboud Universiteit, Academiezaal Aula, Comeniuslaan 2
Stanley Lambertus (1987) started his medical study in 2006 at the Radboud University in Nijmegen, and successfully completed this in 2012. His interest in research and ophthalmology developed in his final year, in which he took part in clinical ophthalmologic research on Stargardt disease at the Radboud university medical center. After his medical studies, he continued research in a PhD project on Stargardt disease, which resulted in this thesis. In March 2017, he started a residency in ophthalmology in the same institute.
- Promotor(s): Prof. C.B. Hoyng, prof. G.J. van der Wilt, prof. B.J. Klevering"